Heidelberg ImmunoTherapeutics GmbH is based in Heidelberg, Germany, and located in the new Bahnstadt area. We are a biopharmaceutical company focusing on the clinical development of innovative, antibody-based immunotherapeutics for the treatment of viral diseases and cancer.
The company was founded as spin-off from the German Cancer Research Center (DKFZ) and Heidelberg University Hospital in 2016. Our goal is to advance novel immunotherapeutics from preclinical research towards early Phase I and II clinical studies.
At Heidelberg ImmunoTherapeutics, a motivated and talented team of scientists, clinical developers and clinicians is working together to develop proprietary drug candidates with potential for making a difference to patients.